Unlocking Cell Therapy
There remain numerous obstacles to successfully treating solid tumors, including:
Poor immune cell infiltration into, and survival within, these tumors
Immunosuppressive properties of the tumor microenvironment (TME)
Lack of tumor selectivity of target antigens which leads to issues with systemic toxicity
Reprogramming the TME using T-SIGn® viral vectors could enable a variety of CAR-T and other cell therapies to overcome such limitations and lead to successful treatment for a variety of different solid tumors.
Preclinical human tumor xenograft studies have demonstrated that T-SIGn viral vectors (expressing transgenes designed to reprogram the TME and drive immune cell recruitment and activation) potently synergize with CAR T-cells of different specificities to clear both primary and metastatic tumors:
Gene expression profiling demonstrated T-SIGn-mediated TME reprogramming and enhanced T-cell activation, as well as recruitment of innate immune cells into the tumors
Transgene payloads were shown to drive the efficacy of T-SIGn/CAR-T combination
Metastases in lungs were also synergistically cleared in this system
T-SIGn viral vectors can be exquisitely designed to specifically synergize with different engineered cellular therapies, including the expression of target antigens and ligands that enhance activation, survival and functional properties of the cells.
Cell-based therapies, particularly those based on T-cells expressing a chimeric antigen receptor (CAR T-cells), have proven to be highly effective for patients with hematological cancers.